Advanced Search
WANG Yongqiang, YE Ting, LIU Jinbo. DNA Methylation Profile of Tumor Suppressor Genes in Diagnosis of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1330-1334. DOI: 10.3971/j.issn.1000-8578.2014.12.017
Citation: WANG Yongqiang, YE Ting, LIU Jinbo. DNA Methylation Profile of Tumor Suppressor Genes in Diagnosis of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1330-1334. DOI: 10.3971/j.issn.1000-8578.2014.12.017

DNA Methylation Profile of Tumor Suppressor Genes in Diagnosis of Primary Hepatocellular Carcinoma

More Information
  • Received Date: February 10, 2014
  • Revised Date: June 30, 2014
  • Objective To investigate the value of promoter methylation status of cancer suppressor genes, such as beclin 1, RASSFA-1, p16, DAPK, etc., and the joint detection in the screening and early diagnosis of hepatocellular carcinoma(HCC). Methods Methylation-specific PCR (MSP) method was used to detect the promoter methylation status of 37 HCC samples and the corresponding tumor adjacent specimens. The area under the ROC curve (AUC) of beclin 1, RASSFA-1, p16, DAPK and stepwise LR results were compared by sensitivity, specificity, Youden index and positive/negative likelihood ratio. Results The positive rates of promoter methylation of beclin 1, RASSFA-1, p16 and DAPK genes in HCC were 5.4% (2/37), 94.6% (35/37), 73.0% (27/37) and 35.1% (13/37), Methylation of RASSFA-1, p16 and DAPK genes was more frequent in HCC than that in adjacent tissues(P<0.05). Combined detection of RASSFA-1 promoter methylation and AFP tumor marker could significantly increase the sensitivity (95.0%) and specificity (97.3%) and the area of ROC(0.903)in the diagnosis of HCC, and obtain higher sensitivity, Youden index and positive/negative likelihood ratio than single gene methylation. Conclusion Joint detection of RASSFA-1 promoter methylation and AFP tumor marker may become an effective index for screening and early diagnosis of HCC.
  • [1]
    Das PM, Singal R. DNA methylation and cancer[J]. J Clin Oncol, 20 04, 22: 4632-42.
    [2]
    Li Z, Chen B, Wu Y, et al. Genetic and epigenetic silencing of the beclin1 gene in sporadic breast tumors[J]. BMC Cancer, 2010, 10: 98.
    [3]
    Endoh H, Yatabe Y, Shimizu S, et al. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication[J]. Int J Cancer, 2003, 106(1): 45-51.
    [4]
    Abbaszadegan MR, Moaven O, Sima HR, et al. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer[J]. World J Gastroenterol, 2008, 14(13): 2055-60.
    [5]
    Kato K, Iida S, Uetake H, et al. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer[J]. Int J Cancer, 2008, 122(3): 603-8.
    [6]
    Ni J, Chen HY, Cao N, et al. Effects of folate with different oxidative states on genomic DNA methylation in human lymphoblast cell line[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41 (03): 256-9. [倪娟, 陈海燕, 曹能, 等. 不同氧化态叶酸对人成 淋巴细胞系基因组DNA甲基化水平的影响[J]. 肿瘤防治研究, 20 14, 41(03): 256-9.]
    [7]
    De Zhu J. The altered DNA methylation pattern and its implications in liver cancer[J]. Cell Res, 2005, 15(4): 272-80.
    [8]
    Li Z, Chen B, Wu Y, et al. Genetic and epigenetic silencing of the Beclin1 gene in sporadic breast tumors[J]. BMC Cancer, 2010, 10 : 98.
    [9]
    Zhang XF, Yin ZF, Wang K, et al. Changes of serum alphafetoprotein and alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma: prognostic significance[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(6): 618-23.
    [10]
    Fei BJ, Huang ZH, Hua D, et al. Clinical significance of methylation of plasma Ras-association domain family 1A gene in the molecular diagnosis of hepatocellular carcinoma[J]. Zhong Liu, 2011, 31(8): 742-7.[费伯健, 黄朝晖, 华东, 等. 血浆Ras相关 区域家族蛋白1A基因甲基化在肝细胞癌分子诊断中的价值[J]. 肿瘤, 2011, 31(8): 742-7.]
    [11]
    Qiu XQ, Chen G, Yu HP, et al. Detection of RASSF1A promoter hypermethylation in plasma of patients with primary hepatocellular carcinoma and its clinical significance[J]. Shi Jie Hua Ren Xiao Hua Za Zhi, 2009, 17(1): 90-3. [仇小强, 陈罡 ,余红平, 等. 肝癌患 者血液RASSF1A基因甲基化的检测及其临床意义[J]. 世界华人 消化杂志, 2009, 17(1): 90-3.]
    [12]
    Yu CH. SPSS and statistic analysis[M]. Beijing: Publishing House of Electronics Industry, 2007: 356-408. [宇传华. SPSS与统计分 析[M] 北京: 电子工业出版社, 2007: 356-408.]
    [13]
    Zhou XJ, Xue WJ, Qin L, et al. Epigenetic inactivation and clinical significance of tumor suppressor gene RASSF1A in hepatocellular carcinoma[J]. Jiangsu Yi Yao, 2007, 33(1): 24-7. [周晓俊, 薛万江, 秦磊, 等. 原发性肝癌中RASSF1A基因表达失活及其临床意义 [J] 江苏医药, 2007, 33(1): 24-7.]
  • Related Articles

    [1]HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi. Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 913-916. DOI: 10.3971/j.issn.1000-8578.2018.18.0265
    [2]LI Daojun, XU Xinhua, ZHANG Jianyu, LI Cong. Clinical Observation of Olanzapine in Treatment of Nausea and Vomiting Caused by Opioid Analgesics[J]. Cancer Research on Prevention and Treatment, 2018, 45(5): 326-328. DOI: 10.3971/j.issn.1000-8578.2018.17.1275
    [3]DONG Shuang, WANG Jun, HU Sheng, LIAO Guoxiang, RAN Fengming. Aprepitant versus Olanzapine for Prevention of Nausea and Vomiting Induced by Multi-day Chemotherapy in Female Lung Cancer or Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 356-359. DOI: 10.3971/j.issn.1000-8578.2017.05.009
    [4]LI Quanfu, Jin gaowa, WANG Wenjuan, JIANG Caihong, DENG Shuqin, LI Hui, CHEN Feng, BAI Xiaojun, CHEN Gang, HU Yuliang, ZHAO Jun, Dalenggaowa, Wuyungaowa. Clinical Observation of Neurokinin-1 Antagonist Preventing Multiple-day Chemotherapy-induced Nausea and Vomiting[J]. Cancer Research on Prevention and Treatment, 2017, 44(4): 290-294. DOI: 10.3971/j.issn.1000-8578.2017.04.011
    [5]LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
    [6]DONG Shuang, YU Shiying. A Study of Chemotherapy-induced Nausea and Vomiting Involving Different Dosage Regimens of Cisplatin[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 890-893. DOI: 10.3971/j.issn.1000-8578.2013.09.016
    [7]Xu Lu, Li Chunlai, Li Ling. A Constructive Experimental Study on Prevention of Chemotherapy-induced Nausea and Vomiting by Ginger-partitioned Moxibustion on Acupoint of Zusanli[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 710-712. DOI: 10.3971/j.issn.1000-8578.2012.06.024
    [8]XU Shu, LI Hong, SONG Yu-hong, LI Bin, CAI Hong-bing. Clinical Comparative of Tropisetron Hydrochloride with or without Traditional Chinese Medicine Compound in Prevention of Chemotherapy-induced Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 787-790. DOI: 10.3971/j.issn.1000-8578.2009.09.021
    [9]MA Lei, MA Hai-long, ZHAO Xu-lin, et al. A Clinical Observation of Tropisetron in Combination with Dexame thasone and Methclopramide in the prevention of High Dose Cisplatin- induced Delayed Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 469-470. DOI: 10.3971/j.issn.1000-8578.474
    [10]Chen Zhendong, . Medroxyprogesterone Acetate with Antiemetics: Efficacy in ControllingAnorexia, Nausea and Vomiting Induced by Chemotherapy[J]. Cancer Research on Prevention and Treatment, 1996, 23(2): 102-103.

Catalog

    Article views PDF downloads Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return